Home / Stocks / Sai Parenterals Limited
SAIPARENT

Sai Parenterals Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹495.4

Change

-6.35 (-1.27%)

Open

₹501.75

Prev. Close

₹501.75

Day High

₹514.1

Day Low

₹487.0

Volume Analysis

Traded

153,543

Delivered

47,036

Delivery %

30.63%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Low return on equity (4.88%)

Opportunities (2)

  • •Strong 3-year EPS growth (39.5%)
  • •Strong 3-year revenue growth (57.8%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹537.76 ₹525.93 ₹510.66 ₹498.83 ₹483.56 ₹471.73 ₹456.46
Fibonacci ₹525.93 ₹515.58 ₹509.18 ₹498.83 ₹488.48 ₹482.08 ₹471.73
Camarilla ₹502.85 ₹500.37 ₹497.88 ₹498.83 ₹492.92 ₹490.43 ₹487.95

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-1.34%

1 Month

+5.95%

3 Months

-8.4%

6 Months

+1.79%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹90.22

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

2.89%

Net margin 3.74% × asset turnover 0.29x × equity multiplier 2.66x

Company Overview

Sector

Healthcare

Market Cap

₹2,189 Cr

P/E (TTM)

87.8

ROE

4.88%

Book Value

₹112.0

Face Value

₹5.0

Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.

TopFund Analysis

Sai Parenterals Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Growth (100/100), while Institutional Ownership (18/100) is the weakest area to weigh before deciding. Notably: Low return on equity (4.88%). FII holding has been falling.

TopFund Score — Fundamentals Quality

50/100 — Average

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

74

Growth

100

Valuation

22

Cash Flow

42

Corporate Governance

56

Momentum

31

Institutional Ownership

18

Business Quality

39

Risk & Volatility

71

Liquidity

28

From Screener.in

  • +Debtor days have improved from 253 to 173 days.
  • −Stock is trading at 4.41 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −Tax rate seems low

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Subsidiary SP Analytics to acquire majority stake in Bion Therapeutics’ prescription business by month-end.

Call conducted on Monday the 2nd day of November, 2026.

Un-audited financial results for the quarter and half-year ended 30th September, 2026.

Audio recording of Q2 FY2027 earnings call held on 2 November 2026 is now available.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 33 54 96 198 179 195
Expenses + 29 42 100 172 155 155
Operating Profit 5 11 -4 26 24 40
OPM % 14.0% 21.0% -3.7% 13.0% 13.0% 21.0%
Other Income + 1 1 3 3 4 4
Interest 2 2 5 8 9 9
Depreciation 1 1 6 8 8 25
Profit before tax 2 9 -12 12 10 10
Tax % 30.0% 31.0% -43.0% -6.0% 19.0% -6.0%
Net Profit + 1 6 -7 13 8 11
EPS in Rs 0 2 -2 3 2 2
Raw PDF — — — — — —
YoY Sales growth — — — — 435 264

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 97 154 163 381 668
Expenses + 78 122 124 342 581
Operating Profit 19 32 39 39 86
OPM % 19.0% 21.0% 24.0% 10.0% 13.0%
Other Income + 0 1 1 9 13
Interest 6 11 12 19 32
Depreciation 6 9 8 17 47
Profit before tax 7 13 20 12 20
Tax % 40.0% 33.0% 28.0% -20.0% —
Net Profit + 4 8 14 14 25
EPS in Rs 1 2 4 3 5
Dividend Payout % 0.0% 0.0% 0.0% 0.0% —
Sales growth — 59 6 134 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 24 61 80 469 184
Borrowings + 69 119 94 469 374
Other Liabilities + 34 75 85 465 450
Total Liabilities 134 268 272 1,424 1,320
Fixed Assets + 44 70 53 364 377
CWIP 2 0 0 212 269
Investments 0 0 0 0 0
Other Assets + 88 198 219 848 674
Total Assets 134 268 272 1,424 1,320
Equity Capital 7 13 13 22 312

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -13 -30 33 93
Cash from Investing Activity + -19 -46 0 -274
Cash from Financing Activity + 24 79 -36 596
Net Cash Flow -8 2 -2 415
Free Cash Flow -30 -72 41 -184
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -54 -94 86 253

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 51.16% → 51.16%
  Mar 2026 Jun 2026 Sep 2026
Public 30.25% 36.29% 38.16%
Promoters 51.16% 51.16% 51.16%
FII 5.73% 4.03% 2.85%
DII 12.86% 8.52% 7.83%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sai Parenterals Limited (this stock) 2,189 87.8 4.42 4.88%
Dishman Carbo Amcis Ltd 2,183 151.0 0.33 1.58%
Sakar Healthcare Limited 2,172 50.7 6.26 9.99%
Panacea Biotec Ltd 2,171 — 2.6 -2.42%
Vimta Labs Limited 2,230 36.7 6.46 13.5%
Indoco Remedies Ltd. 2,079 — 2.03 -9.36%
Windlas Biotech Limited 2,067 31.1 3.64 12.2%

Which Mutual Funds Hold Sai Parenterals Limited?

Frequently Asked Questions about Sai Parenterals Limited

Community Sentiment

What are other investors saying about Sai Parenterals Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.